Table 2 Unadjusted and adjusted prevalence ratios and 95% confidence intervals for ART uptake and viral suppression

Discordance status

 Sero-Discordant

4.6 (2.5–8.3)

2.8 (1.1–6.8)

4.4 (2.4–7.9)

1.5 (0.6–3.9)

3.9 (2.2–7.1)

1.4 (0.5–3.4)

4.4 (2.4–8.1)

1.9 (0.8–4.5)

 Sero-Concordant

Ref

–

–

–

–

–

–

–

Age (years)

 18–24

Ref

–

–

–

–

–

–

–

 25–39

1.5 (0.3–7.1)

2.3 (0.3–17.3)

0.7 (0.1–3.6)

0.2 (0.0–2.1)

0.5 (0.1–2.8)

0.2 (0.0–1.5)

0.4 (0.1–2.1)

0.1 (0.0–0.9)

 40–49

2.4 (0.5–11.8)

2.7 (0.3–23.2)

1.0 (0.2–5.5)

0.3 (0.0–2.8)

0.9 (0.2–5.2)

0.3 (0.0–3.1)

0.8 (0.2–4.6)

0.2 (0.0–2.1)

 50 + 

5.5 (1.0–29.7)

5.0 (0.5–48.6)

2.9 (0.4–18.0)

0.6 (0.1–8.0)

2.2 (0.4–13.0)

0.5 (0.1–7.0)

2.2 (0.4–13.0)

0.5 (0.0–5.2)

Gender

 Man

Ref

–

–

–

–

–

–

–

 Woman

0.6 (0.3–0.9)

0.9 (0.4–2.1)

0.5 (0.3–0.8)

–

0.5 (0.3–0.8)

–

0.5 (0.3–0.8)

–

Marital status

 Single

Ref

–

–

–

–

–

–

–

 Married

8.8 (0.9–86.2)

6.4 (0.3–121.7)

7.6 (0.8–74.2)

–

6.2 (0.6–60.0)

–

5.2 (0.5–51.1)

–

 Divorced/Widowed/ Separated/Other

4.0 (0.3–60.3)

21.8 (0.7–654.7)

3.0 (0.2–42.6)

–

3.0 (0.2–42.5)

–

1.8 (0.1–26.2)

–

Site

 Uganda

Ref

–

–

–

–

–

–

–

 Kericho, Kenya

8.9 (4.2–19.1)

29.4 (6.3–134.6)

7.6 (3.6–16.0)

3.9 (1.3–11.3)

6.0 (2.9–12.4)

3.1 (1.1–8.8)

5.0 (2.5–10.1)

2.4 (0.9–6.6)

 Kisumu, Kenya

5.5 (1.9–16.0)

32.5 (5.5–192.3)

2.8 (1.1–7.2)

1.3 (0.3–5.2)

2.4 (0.9–6.2)

1.1 (0.3–4.3)

2.3 (0.9–5.6)

1.1 (0.3–4.0)

 Tanzania

1.2 (0.5–3.3)

3.6 (0.6–20.3)

1.3 (0.5–3.6)

2.2 (0.5–8.9)

0.6 (0.2–1.6)

0.5 (0.1–2.3)

0.6 (0.2–1.8)

0.7 (0.2–2.9)

 Nigeria

1.9 (0.7–5.1)

13.1 (2.1–79.2)

1.4 (0.5–3.7)

1.3 (0.3–5.4)

1.2 (0.5–3.2)

1.1 (0.3–4.4)

0.9 (0.4–2.6)

1.0 (0.3–3.7)

Duration on ART

 ART Naive

N/A

–

Ref

–

–

-

–

–

  > 0 months to ≤ 6 months

–

–

10.3 (3.4–31.0)

13.3 (3.9–46.0)

6.9 (2.6–18.7)

10.5 (3.3–33.6)

3.6 (1.4–9.5)

5.2 (1.7–15.8)

  > 6 months to ≤ 5 years

–

–

29.3 (12.8–67.5)

23.6 (9.6–58.3)

27.3 (12.4–60.1)

22.4 (9.4–53.4)

19.5 (9.4–40.6)

16.7 (7.3–38.1)

  > 5 years

–

–

48.1 (15.8–146.5)

27.5 (8.2–92.5)

39.9 (15.0–106.1)

19.9 (6.8–57.9)

36.1 (14.1–92.0)

19.5 (6.9–55.0)

Year enrolled in cohort

–

–

 2013

Ref

–

–

–

–

–

–

–

 2014

1.0 (0.4–2.4)

0.1 (0.0–0.5)

0.9 (0.4–2.0)

–

0.7 (0.3–1.5)

–

0.9 (0.4–1.9)

–

 2015

0.7 (0.3–1.8)

0.2 (0.0–1.1)

0.6 (0.2–1.3)

–

0.4 (0.2–1.0)

–

0.6 (0.2–1.3)

–

 2016

1.3 (0.4–3.7)

0.4 (0.1–2.5)

1.5 (0.5–4.5)

–

1.5 (0.5–4.5)

–

1.9 (0.7–5.3)

–

 2017

0.3 (0.1–2.7)

0.2 (0.0–4.1)

0.1 (0.0–1.2)

–

0.1 (0.0–1.2)

–

0.2 (0.0–1.8)

–

WHO stage

 I

Ref

–

–

–

–

–

–

–

 II

3.4 (1.9–6.2)

3.5 (1.6–7.6)

3.0 (1.7–5.3)

2.0 (0.8–4.6)

3.0 (1.7–5.3)

2.1 (0.9–4.9)

2.9 (1.7–5.0)

1.6 (0.7–3.5)

 III and IV

19.5 (4.4–86.1)

25.4 (4.5–143.2)

5.0 (2.0–12.6)

2.3 (0.6–8.4)

4.5 (2.0–10.7)

2.2 (0.7–7.3)

4.6 (2.0–10.7)

2.0 (0.6–6.0)

Status disclosure to partner

 Yes

1.6 (0.8–3.4)

1.1 (0.2–7.6)

3.7 (1.4–9.5)

–

3.7 (1.4–9.8)

–

4.0 (1.5–10.8)

–

 No

Ref

–

–

–

–

–

–

–